Anti-phospholipid antibodies in patients with multiple sclerosis and MS-like illnesses: MS or APS?

Abstract

Objective: To describe the frequency, clinical, and laboratory features of patients diagnosed with multiple sclerosis (MS) or MS-like illnesses (MSL) among a large, prospectively followed cohort of anti-phospholipid antibody (aPL)-positive patients.

Methods: Between 1990 and 1995 patients referred to a university-affiliated rheumatology clinic were prospectively evaluated for aPL based on questionnaires designed to detect aPL-related symptoms and/or a family history of aPL-related illnesses. Magnetic resonance imaging (MRI) was performed when significant neurological features were present. A subgroup of all patients diagnosed with MS or MSL was identified and their clinical, laboratory, and imaging findings were reviewed.

Results: Of 322 patients evaluated for aPL-related symptoms or events, 189 (59%) were positive for at least one class of aPL. Twenty-six of 322 patients (8%) carried a diagnosis of MS or MSL, either at the initial evaluation or during the study period. Twenty-three of the 26 individuals (88%) tested positive for aPL, while the remaining 3 (11%) tested repeatedly negative. Eighteen of the 23 patients (78%) had either more than one class of aPL or had multiple positive titers. IgM aCL was noted in 18 of the 23 patients (78%). Oligoclonal bands were noted in five patients. Antinuclear antibodies (ANA) and low complement levels were frequently observed. Blinded MRI readings showed lesions consistent with MS in the majority of cases. Clinically, 7 patients had transverse myelitis (TM), while optic neuritis (ON) was present in 8 patients. Most patients had either occult symptoms of rheumatic disease or contributory family histories. None had a defined underlying connective-tissue disease.

Conclusion: A substantial number of aPL-positive patients have a concurrent diagnosis of MS or MSL, frequently presenting with elevated IgM aCL, optic neuritis, and transverse myelitis. The anti-phospholipid syndrome (APS) should be strongly considered as an alternative diagnosis to MS in these patients.

Keywords

ANA anti-phospholipid antibody lupus multiple sclerosis

Get full access to this article

View all access options for this article.

References

Petri M . Pathogenesis and treatment of the antiphospholipid antibody syndrome . Med Clin North Am 1997; 81: 151–177 .

Gharavi AE , Wilson WA . The syndrome of thrombosis, thrombocytopenia, and recurrent spontaneous abortions associated with antiphospholipid antibodies: Hughes syndrome . Lupus 1996; 5: 343–344 .

Hughes GRV . The antiphospholipid syndrome . Lupus 1996; 5: 345–346 .

Piette J-C . 1996 Diagnostic and classification criteria for the antiphospholipid/cofactors syndrome: a mission impossible? Lupus 1996; 5: 354–363 .

Lie JT . Vasculopathy of the antiphospholipid syndrome revisited: thrombosis is the culprit and vasculitis the consort . Lupus 1996; 5: 368–371 .

Levy RA . Clinical manifestations of the aPL syndrome . Lupus 1996; 5: 393–397 .

Asherson RA , et al. The “primary” antiphospholipid syndrome: major clinical and serological features . Medicine (Baltimore) 1989; 68: 366–374 .

Vianna JL , et al. Comparison of the primary and secondary antiphospholipid syndrome: a European Multicenter Study of 114 patients . Am J Med 1994; 96: 3–9 .

Rosove MH , Brewer PM . Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients . Ann Intern Med 1992; 117: 303–308 .

10.

Love PE , Santoro SA . Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders . Ann Intern Med 1990; 112: 682–698 .

11.

Petri M . Diagnosis of antiphospholipid antibodies . Rheum Dis Clin North Am 1994; 20: 443–469 .

12.

Lockshin MD . Antiphospholipid antibody syndrome . Rheum Dis Clin North Am 1994; 20: 45–59 .

13.

Bick RL , Baker WF . The antiphospholipid and thrombosis syndromes . Med Clin North Am 1994; 78: 667–684 .

14.

Harris N . Antiphospholipid syndrome. In: Klippel J , Dieppe P (eds) Rheumatology. Mosby: St Louis , 1994, Section 6:32:31–6:32:36.

15.

Levine SR , Brey RL . Neurological aspects of antiphospholipid antibody syndrome . Lupus 1996; 5: 347–353 .

16.

Brey RL , Gharavi AE , Lockshin MD . Neurologic complications of antiphospholipid antibodies . Rheum Dis Clin North Am 1993; 19: 833–850 .

17.

O'Neill D , Magaldi J , Dobkin D , Greco T . Dissolution of intracardiac mass lesions in the primary antiphospholipid antibody syndrome . Arch Intern Med 1995; 155: 325–327 .

18.

Lavalle C , et al. Transverse myelitis; a manifestation of systemic lupus erythematosus strongly associated with antiphospholipid antibodies . J Rheumatol 1990; 17: 34–37 .

19.

Scott TF , Hess D , Brillman J . Antiphospholipid antibody syndrome mimicking multiple sclerosis clinically and by magnetic resonance imaging . Arch Intern Med 1994; 154: 917–920 .

20.

Poser CM , et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols . Ann Neurol 1983; 13: 227–231 .

21.

Gharavi AE , Harris EN , Asherson RA , Hughes GRV . Anticardiolipin antibodies: isotype distribution and phospholipid specificity . Ann Rheum Dis 1987; 46: 1–6 .

22.

Goldberg SN , Conti-Kelly AM , Greco TP . A family study of anticardiolipin antibodies and associated clinical conditions . Am J Med 1995; 99: 473–479 .

23.

Harris EN , Gharavi AE , Patel SP , Hughes GRV . Evaluation of the anticardiolipin antibody test: report of standardization workshop held April 4th, 1986 . Clin Exp Immunol 1987; 68: 215–222 .

24.

Fukazawa T , Moriwaka F , Mukai M , Koike T , Tashiro K . Antic-ardiolipin antibodies in Japanese patients with multiple sclerosis . Acta Neurol Scand 1993; 88: 184–189 .

25.

Sugiyama Y , Yamamoto T . Characterization of serum anti-phospho-lipid antibodies in patients with multiple sclerosis . Tohoku J Exp Med 1996; 178: 203–215 .

26.

Harada T , et al. Visual function in patients with optic neuritis associated with acute transverse myelopathy in multiple sclerosis . Jpn J Ophthal 1993; 39: 290–294 .

27.

Oppenheimer S , Hoffmand B . Optic neuritis and myelopathy in systemic lupus erythematosus . Can J Neurol Sci 1986; 13: 129–132 .

28.

Rombos A , et al. Serum IgG and IgM anticardiolipin antibodies in neurological diseases . Acta Neurol Scand 1990; 81: 234–245 .

29.

Poser CM . The epidemiology of multiple sclerosis: a general overview . Ann Neurol 1994; 36: 80–193 .

30.

Rolak LA . The diagnosis of multiple sclerosis . Neurol Clin North Am 1996; 14: 27–43 .

31.

Barned S , Goodman AD , Mattson DH . Frequency of antinuclear antibodies in multiple sclerosis . Neurology 1995; 45: 384–385 .

32.

Michielsens B , Walravens M , Vermylen J , Carton H . Diagnostic significance of antinuclear antibodies in neurologic patients . Acta Neurol Scand 1991; 84: 102–106 .

33.

Davis WD , Brey RL . Antiphospholipid antibodies and complement activation in patients with cerebral ischemia . Clin Exp Rheum 1992; 10: 455–460 .

34.

Ferro D , et al. Transient antiphospholipid antibodies (APLA) positivity in patients with primary antiphospholipid syndrome . Lupus 1996; 5: 551–551 (abstract).

35.

Reber G , et al. Multicenter evaluation of nine commercial kits for the quantitation of anticardiolipin antibodies . Thromb Haemost 1995; 73: 444–452 .

36.

Triplett DA . Protean clinical presentation of antiphospholipid-protein antibodies (APA) . Thromb Haemost 1995; 74: 329–337 .

37.

Cines DB , McCrae KR . The antiphospholipid-protein syndrome . J Clin Immunol 1995; 15: 86S–100S .

38.

Alarcon-Segovia D , Cabral AR . The concept and classification of antiphospholipid/cofactor syndromes . Lupus 1996; 5: 364–367 .

39.

Kandiah DA , Sheng YH , Krilis SA . Beta 2-glycoprotein I: target antigen for autoantibodies in the ‘antiphospholipid syndrome’ . Lupus 1996; 5: 381–385 .

40.

Roubey RA . Antigenic specificities of antiphospholipid autoantibodies: implications for clinical laboratory testing and diagnosis of the antiphospholipid syndrome . Lupus 1996; 5: 425–430 .